Therapeutic Response

BRAF p.V600E status confers therapeutic sensitivity to Binimetinib in combination with Encorafenib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Braftovi (encorafenib) [product information]. EMA. The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
Mektovi (binimetinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.
Braftovi (encorafenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to encorafenib in combination with binimetinib for the treatment of adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation, as detected by an FDA-approved test. Encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.
Mektovi (binimetinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.